Netherlands· NL-e637dda65c6f

EDURANT 2,5 mg dispergeerbare tabletten

A rilpivirine product containing rilpivirinehydrochloride, registered in Netherlands by Janssen-Cilag International NV. The same ATC class is registered in 14 of our 19 countries.

ATC J05AG05

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about rilpivirinehydrochlorideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Rilpivirine is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AG05 (rilpivirine), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search rilpivirine products by name

Rilpivirine · ATC J05AG05

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rilpivirine costs, country by country.

Normalised to the WHO defined daily dose (25 mg), the median price runs from $6.77 in France to $13.46 in Switzerland — a ×2.0 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Rilpivirine · price per daily dose (25 mg)

USD · FX 28 Sept 2026

CH Switzerland$13.46
FR France$6.77

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RILPIVIRINEHYDROCHLORIDE
Manufacturer: Janssen-Cilag International NV
Country: Netherlands (NL)
ATC code: J05AG05
ATC class: Rilpivirine
Defined daily dose: 25 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/11/736

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

239 interactions on record for rilpivirine.

Graded by severity as the source publishes them — 58 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check rilpivirine against other medicines How interaction checks work

Rilpivirine · interactions on record

239 records

58 severe
179 moderate
2 minor

Most severe, free to view

CimetidineA02BA01severe
RanitidineA02BA02severe
FamotidineA02BA03severe
NizatidineA02BA04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rilpivirine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rilpivirine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Edurant, Rekambys
Liechtenstein · Edurant, Rekambys
Norway · Edurant, Rekambys

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/63086e08-7fe2-4a25-b5cb-203fa71754e9
GET /v1/drugs/63086e08-7fe2-4a25-b5cb-203fa71754e9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispergeerbare tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/edurant-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Rilpivirine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131994",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "LACTOSE 1-WATER",
    "MANNITOL (D-) (E 421)",
    "NATRIUMLAURILSULFAAT",
    "NATRIUMSTEARYLFUMARAAT",
    "POLYSORBAAT 20 (E 432)",
    "POVIDON K 30 (E 1201)"
  ],
  "substances": [
    "RILPIVIRINEHYDROCHLORIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/09/19",
  "procedure_number": "EMEA/H/C/002264",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/11/736",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about rilpivirine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console